Add-on Acquisition • Life Science

Ethypharm Acquires Martindale Pharmaceuticals

On January 19, 2017, Ethypharm acquired life science company Martindale Pharmaceuticals from AAC Capital UK

Acquisition Context
  • This is Ethypharm’s 1st transaction in the Life Science sector.
  • This is Ethypharm’s 2nd transaction in the United Kingdom.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date January 19, 2017
Target Martindale Pharmaceuticals
Sector Life Science
Buyer(s) Ethypharm
Sellers(s) AAC Capital UK
Deal Type Add-on Acquisition

Target Company

Martindale Pharmaceuticals

Brentwood, United Kingdom
Martindale Pharmaceuticals Ltd. is a niche manufacturer and supplier of specialty pharmaceutical products and services, including Unlicensed medicines (‘Specials’), injectables, pre-filled syringes and oral solutions. Martindale has a diverse portfolio of over 200 licensed compounds and a proprietary database of 30,000 formulations for Specials. Martindale’s in-house expertise covers the full product lifecycle from formulation, to product development, registration and licensing, manufacturing and full quality monitoring and testing.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Ethypharm

SaintCloud, France

Category Company
Founded 1977
Sector Life Science
Employees810
Revenue 186M EUR (2015)
DESCRIPTION

Ethypharm is a Drug Delivery System (DDS) company. The company develops and manufactures medicinal products specialising in controlled release products. Drug Delivery Systems provide major benefits including improving the drug efficacy, enhancing patient compliance and comfort, extending the life cycle of existing drugs, and reducing the total cost of treatment. Ethypharm was founded in 1977 and is based in SaintCloud, France.


Deal Context for Buyer #
Overall 2 of 3
Sector: Life Science 1 of 2
Type: Add-on Acquisition 2 of 2
Country: United Kingdom 2 of 2
Year: 2017 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-01 DB Ashbourne

Leicestershire, United Kingdom

DB Ashbourne Ltd. is a branded pharmaceutical business.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-18 Altan Pharma

Dublin, Ireland

Altan Pharma is a pharmaceutical company that develops, manufactures, and markets injectable medications for the hospital and other provider segments. Altan Pharma was founded in 2015 and is based in Dublin, Ireland.

Buy -

Seller Profile 1

SELLER

AAC Capital UK

London, United Kingdom

Category Private Equity Firm
Founded 2011
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

AAC Capital UK is a mid-market Private equity buyout firm focuses on the niche companies in the Industrial, Business Services and Consumer sectors. AAC Capital UK formerly known as the UK team of ABN AMRO Capital. The firm looks to invest in profitable, cash-generative companies whose principal operations are in the UK. AAC Capital UK LLP is a private equity arm of AAC Capital partners. AAC Capital UK was formed in 2011 and is based in UK.


Deal Context for Seller #
Overall 18 of 21
Sector: Life Science 1 of 1
Type: Add-on Acquisition 11 of 12
Country: United Kingdom 16 of 19
Year: 2017 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-10 NSL Services Group

London, United Kingdom

NSL Services Group Ltd. is a niche Local Authority (‘LA’) and Government outsourcing business which is divided into four operational divisions: Enforcement Solutions, Passenger Transport, Business Process Outsourcing and Consultancy.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-23 James Dewhurst

Altham, United Kingdom

James Dewhurst Ltd. is a manufacturer of woven and non-woven technical textiles used in a wide range of applications to improve the performance of its customers' end products and processes. James Dewhurst Ltd. was founded in 1933 and is based in Altham, United Kingdom.

Sell £44M